Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
Angeli, A., Tanini, D., Peat, T.S., Di Cesare Mannelli, L., Bartolucci, G., Capperucci, A., Ghelardini, C., Supuran, C.T., Carta, F.(2017) ACS Med Chem Lett 8: 963-968
- PubMed: 28947945 
- DOI: https://doi.org/10.1021/acsmedchemlett.7b00280
- Primary Citation of Related Structures:  
5ULN, 5UMC, 5WEX - PubMed Abstract: 
A series of benzenesulfonamides bearing selenourea moieties was obtained considering the ureido-sulfonamide SLC-0111 , in Phase I clinical trials as antitumor agent, as a lead molecule. All compounds showed interesting inhibition potencies against the physiologically relevant human (h) carbonic anhydrase (hCAs, EC 4.2.1.1) isoforms I, II, IV, and IX. The most flexible analogues in the series 14 - 19 showed low nanomolar inhibition constants against hCA I, II, and IX. We assessed selected compounds on the in vitro antioxidant properties and binding modes and evaluated ex vivo human prostate (PC3), breast (MDA-MB-231), and colon-rectal (HT-29) cancer cell lines both in normoxic and hypoxic conditions.
Organizational Affiliation: 
University of Florence, NEUROFARBA Dept., Sezione di Scienze Farmaceutiche, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Florence, Italy.